Cook MyoSite Incorporated is developing and commercializing technology related to the collection, selection and expansion of human skeletal muscle cells. Separate research and clinical programs have been established to assist the research community in performing muscle-related research and to develop cellular products for the treatment of a variety of muscle-related disorders.
Cook MyoSite is part of Cook Medical, the first company to introduce minimally invasive interventional devices in the United States. Today, Cook Medical participates in all global markets, integrating device design, biopharma, gene and cell therapy and biotech to enhance patient safety and improve clinical outcomes.
In 2002, Cook Medical formed Cook MyoSite to guide the company into the expanding world of cellular technologies. Through pioneering efforts, research involving the use of adult skeletal muscle-derived cells for tissue augmentation is being developed into a treatment option for patients with a variety of muscle-related disorders.
In 2007, Cook MyoSite completed construction on its new facility, which is located 10 miles outside of downtown Pittsburgh, Pennsylvania. Our clinical products are produced in this state-of-the-art ISO Class 7 manufacturing suite to guarantee the highest level of quality.
Carl Cook, MBA
CEO, Cook Group
Richard A. Faulk Jr., MBA
Director of Business Process Management
Ron Jankowski, PhD
Director of Research and Product Development
Ryan Pruchnic, MS, MBA
Director of Operations
Director of Quality
Cook MyoSite is certified with the U.S. Department of Commerce’s Safe Harbor Privacy program for the transfer of clinical study data that pertains to residents of the European Union. Safe Harbor Privacy Program